<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01420861</url>
  </required_header>
  <id_info>
    <org_study_id>G200707</org_study_id>
    <nct_id>NCT01420861</nct_id>
  </id_info>
  <brief_title>GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer</brief_title>
  <official_title>Open Label Study of the Effect of GTx-758 on Serum PSA and Free Testosterone Levels in Men With Castration Resistant Prostate Cancer and Maintained on Androgen Deprivation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GTx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GTx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of GTx-758 on Serum Prostate-specific&#xD;
      antigen (PSA) levels in men with castrate resistant prostate cancer who are maintained on&#xD;
      androgen deprivation therapy (Serum PSA response and Serum PSA progression)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    FDA Clinical Hold&#xD;
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decline in serum PSA</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1000 mg GTx-758</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will receive daily doses of 1000 mg GTx-758</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GTx-758</intervention_name>
    <description>two GTx 758 tablets per day</description>
    <arm_group_label>1000 mg GTx-758</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be over 18 years of age&#xD;
&#xD;
          2. Be able to communicate effectively with the study personnel&#xD;
&#xD;
          3. Have histologically confirmed prostate cancer&#xD;
&#xD;
          4. ECOG performance status of 0 to 2&#xD;
&#xD;
          5. Have been treated with ADT(chemical or surgical) for at least 6 months&#xD;
&#xD;
          6. Have castrate level of serum total testosterone (&lt;50 ng/dL)&#xD;
&#xD;
          7. Have a history of serum PSA response after initiation of ADT, serum PSA response is at&#xD;
             least a 90% reduction in serum PSA to &lt;10 ng/mL OR undetectable level of serum PSA&#xD;
             (less tan or =0.2 ng/mL)&#xD;
&#xD;
          8. Have rising serum PSA on two successive assessments at least 2 weeks apart and serum&#xD;
             PSA levels â‰¥ 2 ng/mL or 2ng/mL and a 25% increase over the nadir after the initiation&#xD;
             of ADT&#xD;
&#xD;
          9. Be continued on androgen deprivation therapy throughout this study&#xD;
&#xD;
         10. Give written informed consent prior to any study specific procedures&#xD;
&#xD;
         11. Subjects must agree to use acceptable methods of contraception:&#xD;
&#xD;
        oIf their female partners are pregnant or lactating acceptable methods of contraception&#xD;
        from the time of the first administration of study medication until 3 months following&#xD;
        administration of the last dose of study medication must be used. Acceptable methods are:&#xD;
        Condom used with spermicidal foam/gel/film/cream/suppository. If the subject has undergone&#xD;
        surgical sterilization (vasectomy with documentation of azospermia) a condom with&#xD;
        spermicidal foam/gel/film/cream/suppository should be used. oIf the male subject's partner&#xD;
        could become pregnant, use acceptable methods of contraception from the time of the first&#xD;
        administration of study medication until 3 months following administration of the last dose&#xD;
        of study medication. Acceptable methods of contraception are as follows: Condom with&#xD;
        spermicidal foam/gel/film/cream/suppository [i.e. barrier method of contraception],&#xD;
        surgical sterilization (vasectomy with documentation of azospermia) and a barrier method&#xD;
        {condom used with spermicidal foam/gel/film/cream/suppository}, the female partner uses&#xD;
        oral contraceptives (combination estrogen/progesterone pills), injectable progesterone or&#xD;
        subdermal implants and a barrier method {condom used with spermicidal&#xD;
        foam/gel/film/cream/suppository}. oIf the female partner has undergone documented tubal&#xD;
        ligation (female sterilization), a barrier method {condom used with spermicidal&#xD;
        foam/gel/film/cream/suppository} should also be used. oIf the female partner has undergone&#xD;
        documented placement of an intrauterine device (IUD) or intrauterine system (IUS) and a&#xD;
        barrier method {condom with spermicidal foam/gel/film/cream/suppository} should also be&#xD;
        used.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity or allergy to estrogen or estrogen like drugs;&#xD;
&#xD;
          2. Have symptomatic metastatic prostate cancer&#xD;
&#xD;
          3. Any disease or condition (medical or surgical) which might compromise the hematologic,&#xD;
             cardiovascular, endocrine, pulmonary, renal, gastrointestinal, hepatic, or central&#xD;
             nervous system; or other conditions that may interfere with the absorption,&#xD;
             distribution, metabolism or excretion of study drug, or would place the subject at&#xD;
             increased risk;&#xD;
&#xD;
          4. History of abnormal blood clotting, Factor V Leiden clotting disorder, thrombotic&#xD;
             disease (venous or arterial thrombotic events such as history of stroke, deep vein&#xD;
             thrombosis (DVT), and/or pulmonary embolus (PE))&#xD;
&#xD;
          5. Symptomatic congestive heart failure (NYHA Class III - IV), unstable angina pectoris,&#xD;
             cardiac arrhythmia&#xD;
&#xD;
          6. The presence of consistently abnormal laboratory values which are considered&#xD;
             clinically significant. In addition, no subject with liver enzymes (ALT or AST) above&#xD;
             2 times the ULN, total bilirubin above 2 times the ULN, or serum creatinine above 1.5&#xD;
             ULN will be admitted to the study&#xD;
&#xD;
          7. Received an investigational drug within a period of 90 days prior to enrollment in the&#xD;
             study&#xD;
&#xD;
          8. Received the study medication previously&#xD;
&#xD;
          9. Currently taking testosterone, testosterone-like agents, or antiandrogens,including&#xD;
             5-alpha reductase inhibitors (may be eligible if allow a 6 week washout period after&#xD;
             stopping antiandrogens);&#xD;
&#xD;
         10. History of prior treatment of cancer chemotherapy agent (other than hormone therapy)&#xD;
             or radiopharmaceutical for prostate cancer.&#xD;
&#xD;
         11. Have taken ketoconazole within the previous 12 months prior to randomization into this&#xD;
             study&#xD;
&#xD;
         12. Have taken diethylstilbestrol or other estrogen products, ketoconazole, or abiraterone&#xD;
             within the previous 12 months prior to randomization into this study&#xD;
&#xD;
         13. Have taken body building or fertility supplements within 4 weeks of admission into the&#xD;
             study&#xD;
&#xD;
         14. Have been previously diagnosed with cancer (other than prostate cancer, superficial&#xD;
             bladder cancer, or non-melanoma skin cancer).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Steiner, MD</last_name>
    <role>Study Director</role>
    <affiliation>GTx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigational Site</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>August 18, 2011</study_first_submitted>
  <study_first_submitted_qc>August 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2011</study_first_posted>
  <last_update_submitted>April 23, 2014</last_update_submitted>
  <last_update_submitted_qc>April 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>castrate resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

